Vincent A. Miller Sells 2,349 Shares of Foundation Medicine Inc (FMI) Stock

Foundation Medicine Inc (NASDAQ:FMI) insider Vincent A. Miller sold 2,349 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $150,336.00. Following the transaction, the insider now directly owns 99,484 shares in the company, valued at approximately $6,366,976. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Foundation Medicine Inc (NASDAQ FMI) opened at $64.95 on Friday. The firm has a market capitalization of $2,285.73, a P/E ratio of -14.53 and a beta of -0.01. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47. Foundation Medicine Inc has a 12-month low of $17.50 and a 12-month high of $70.75.

Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. The business had revenue of $42.66 million during the quarter, compared to analysts’ expectations of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm’s revenue for the quarter was up 45.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.90) earnings per share. equities analysts forecast that Foundation Medicine Inc will post -4.44 EPS for the current year.

Several large investors have recently made changes to their positions in FMI. Teachers Advisors LLC increased its holdings in shares of Foundation Medicine by 5.7% during the first quarter. Teachers Advisors LLC now owns 24,387 shares of the company’s stock worth $786,000 after buying an additional 1,316 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Foundation Medicine by 9.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 60,227 shares of the company’s stock valued at $2,395,000 after purchasing an additional 5,404 shares during the period. Rhumbline Advisers increased its holdings in Foundation Medicine by 9.7% in the second quarter. Rhumbline Advisers now owns 16,628 shares of the company’s stock valued at $661,000 after purchasing an additional 1,470 shares during the period. State of Wisconsin Investment Board acquired a new stake in Foundation Medicine in the second quarter valued at $437,000. Finally, Bank of New York Mellon Corp increased its holdings in Foundation Medicine by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 61,597 shares of the company’s stock valued at $2,449,000 after purchasing an additional 835 shares during the period. Institutional investors own 32.68% of the company’s stock.

A number of research firms recently weighed in on FMI. BidaskClub raised Foundation Medicine from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. Zacks Investment Research cut Foundation Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $45.33.

ILLEGAL ACTIVITY NOTICE: “Vincent A. Miller Sells 2,349 Shares of Foundation Medicine Inc (FMI) Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3126776/vincent-a-miller-sells-2349-shares-of-foundation-medicine-inc-fmi-stock.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.